By Dominic Chopping
--KKR is nearing a deal to buy E45 maker Karo Healthcare in a buyout that values the healthcare company at about 2.6 billion euros ($2.85 billion), Financial Times reports, citing unnamed sources.
--The U.S. private equity group bested a rival bid from PAI Partners to clinch the company behind over-the-counter medicines such as athlete's foot treatment Lamisil and moisturizer E45, paying 2.65 billion euros including debt, the people said, according to FT.
--Karo's current owner, EQT, struck a deal to take the business private in 2022, valuing it at about 1.4 billion euros. EQT first became a majority owner of Karo in 2019 when it was still a publicly-listed business.
-Karo, EQT and PAI declined to comment while KKR did not immediately respond to a request for comment, FT says.
Full story: https://tinyurl.com/4va2f8wt
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
April 09, 2025 01:47 ET (05:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。